Scarica l'app Stockscreener
1.67
4.02%
-0.07
Pre-mercato:
1.73
0.06
+3.59%
Precedente Chiudi:
$1.74
Aprire:
$1.82
Volume 24 ore:
3.95M
Relative Volume:
1.30
Capitalizzazione di mercato:
$118.75M
Reddito:
$391.70K
Utile/perdita netta:
$-52.34M
Rapporto P/E:
-2.2267
EPS:
-0.75
Flusso di cassa netto:
$-45.92M
1 W Prestazione:
-9.24%
1M Prestazione:
+33.60%
6M Prestazione:
+554.90%
1 anno Prestazione:
+53.21%
Intervallo 1D:
$1.65
$1.84
Intervallo di 1 settimana:
$1.57
$1.89
Portata 52W:
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
Nome
Ovid Therapeutics Inc
Settore
Industria
Telefono
212-776-4381
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Confronta OVID con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.67 | 123.73M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-08 | Ripresa | B. Riley Securities | Buy |
| 2024-06-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Iniziato | B. Riley Securities | Buy |
| 2024-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-05 | Iniziato | Wedbush | Outperform |
| 2023-12-21 | Iniziato | BTIG Research | Buy |
| 2023-10-13 | Iniziato | Oppenheimer | Outperform |
| 2021-04-20 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-04-20 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Combining machine learning predictions for Ovid Therapeutics Inc.Weekly Profit Summary & Daily Chart Pattern Signals - newser.com
Is a relief rally coming for Ovid Therapeutics Inc. holdersWeekly Trade Recap & Fast Entry Momentum Trade Alerts - newser.com
Is Ovid Therapeutics Inc. (1OT) stock protected from inflationMarket Performance Summary & Verified Technical Signals - newser.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - Yahoo Finance
Oppenheimer Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID) - MarketBeat
Ovid Therapeutics' (OVID) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Will Ovid Therapeutics Inc. benefit from macro trendsWeekly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Real time pattern detection on Ovid Therapeutics Inc. stock2025 Bull vs Bear & Short-Term Trading Alerts - newser.com
Ovid Therapeutics Inc Stock Analysis and ForecastStock Rotation Strategies & Exceptional Trading Strategies - earlytimes.in
Market reaction to Ovid Therapeutics Inc.’s recent newsRate Hike & Breakout Confirmation Alerts - newser.com
Ovid spikes as Wedbush moves to Outperform on lead asset - MSN
Ovid Therapeutics (OVID) Surges on Positive Analyst Rating - GuruFocus
Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says - MarketScreener
Technical signs of recovery in Ovid Therapeutics Inc.IPO Watch & Risk Controlled Swing Alerts - newser.com
What data driven models say about Ovid Therapeutics Inc.’s futureWeekly Risk Report & High Yield Equity Trading Tips - newser.com
What drives PSP Swiss Property AG Common Stock P7S0 stock priceCapital Gains Strategies & Follow Top Performers in the Community - earlytimes.in
Is Ovid Therapeutics Inc. (1OT) stock vulnerable to rate hikesJuly 2025 Retail & Capital Efficiency Focused Ideas - newser.com
Detecting price anomalies in Ovid Therapeutics Inc. with AITrade Volume Report & Real-Time Buy Zone Alerts - newser.com
Tools to assess Ovid Therapeutics Inc.’s risk profileEarnings Growth Summary & Weekly Chart Analysis and Guides - newser.com
Hudson Yards seizure drug company raises $81M after cutting expenses - Crain's New York Business
What analysts say about Ovid Therapeutics Inc 1OT stockStock Rotation Strategies & Minimal Capital Investment - earlytimes.in
Ovid Therapeutics (OVID): Evaluating Valuation After Positive Phase 1 Trial Results and $175 Million Financing - Sahm
Ovid Therapeutics Inc. (OVID) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know - Yahoo Finance
Wedbush Adjusts Price Target on Ovid Therapeutics to $5 From $3, Maintains Outperform Rating - MarketScreener
What’s next for Ovid Therapeutics Inc. stock priceJuly 2025 Rallies & Stock Timing and Entry Methods - newser.com
Ovid Therapeutics Sets Market Trends with Successful Trials - Kalkine Media
Ovid Therapeutics Inc. announced that it has received $80.8108 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Blue Owl Healthcare Opportunities, ADAR1 Capital Management, LLC, Affinity Asset Advisors, LLC - MarketScreener
Forecasting Ovid Therapeutics Inc. price range with options data2025 Technical Overview & Daily Stock Trend Watchlist - newser.com
Why Ovid Therapeutics Inc. stock is popular among millennialsJuly 2025 Big Picture & Weekly Market Pulse Updates - newser.com
Ovid Therapeutics rises on $175 million placing and research update - The Pharma Letter
Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results - Yahoo Finance
Ovid announces positive topline results for the - GlobeNewswire
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Raises Target Price to $5 - 富途牛牛
Ovid Therapeutics Secures $175.1M in Private Placement - TipRanks
Ovid Therapeutics Inc. announced that it expects to receive $80.8108 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Blue Owl Healthcare Opportunities, ADAR1 Capital Management, LLC, Affinity Asset Advisors, LLC - MarketScreener
Ovid Therapeutics Stock: Analyzing Market Movement - timothysykes.com
Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders - Seeking Alpha
OVID Stock Surge: Opportunity or Risk? - StocksToTrade
Ovid Therapeutics Inc. (OVID) Stock: Rallies as Major Investors Join $175M Private Placement - parameter.io
Ovid Therapeutics Inc. (OVID) Stock: Soars on $81M Initial Funding, PIPE Could Reach $175M - CoinCentral
Wedbush Adjusts Ovid Therapeutics Price Target to $5 From $3, Maintains Outperform Rating - MarketScreener
Ovid Therapeutics (OVID) Surges After Positive Study Results - GuruFocus
Transcript : Ovid Therapeutics Inc.Special Call - MarketScreener
Ovid Therapeutics Surges: Is It a Buy? - StocksToTrade
Ovid Therapeutics Rockets 19% on Game-Changing Epilepsy Drug Breakthrough – Why This Could Shake Up Brain Health Investing - RagingBull
Ovid rises after positive results from epilepsy study (OVID) - Seeking Alpha
Ovid Therapeutics Surge: Market Moves and Metrics - timothysykes.com
Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why - Stocktwits
Ovid Therapeutics Raises $175 Million Through PIPE Financing - Finimize
Ovid Therapeutics (OVID) Secures $175M in PIPE Financing Deal - GuruFocus
Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ovid Therapeutics Inc Azioni (OVID) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | CBFO |
Feb 26 '25 |
Sale |
0.56 |
3,902 |
2,185 |
67,973 |
| ALEXANDER MARGARET A. | President and COO |
Jan 27 '25 |
Buy |
0.73 |
6,810 |
4,971 |
34,935 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):